Study S001377

A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07575399
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 300
Start: 2026-05-11
Primary completion: 2028-01-03
Lead sponsor: Amgen
Conditions: Obesity or Overweight
Interventions: DRUG:Maridebart Cafraglutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent Change from Baseline in Body Weight at Week 68 [Week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.